The company has not filed an annual or quarterly report since its Q1 FY2023 10-Q, filed May 11, 2023. Its latest SEC filing is a 4 from Feb 14, 2024.
10-Q for Q1 FY2023, filed May 11, 2023
The sections below describe the company as of the FY2022 annual report.
Develops engineered T-cell therapies for patients with solid tumors, modifying patients’ own T cells to recognize and attack cancer cells.
10-K for FY2022, filed Mar 23, 2023
No revenue was reported.
10-K for FY2022, filed Mar 23, 2023
10-Q for Q1 FY2023, filed May 11, 2023
−$40.4MView ↗
Trial focus
The older report described the mesothelin program across ovarian, lung, mesothelioma and bile-duct cancers; the latest focuses its development on ovarian cancer with Opdivo and redosing strategies.
10-K for FY2019, filed Mar 30, 2020 10-K for FY2022, filed Mar 23, 2023Our lead TRuC-T cell targeting solid tumors is TC-210. We are conducting our Phase 1/2 clinical trial for TC-210 to treat patients with…View ↗
We designed the Phase 2 portion of our Phase 1/2 clinical trial to assess gavo-cel in patients with ovarian cancer, NSCLC, malignant…View ↗
Pipeline priorities
The older report paired mesothelin-targeting solid-tumor and blood-cancer lead programs; the latest funds mesothelin programs and a program for solid and blood cancers.
10-K for FY2019, filed Mar 30, 2020 10-K for FY2022, filed Mar 23, 2023In September 2022, we announced a refocused pipeline designed to maximize the delivery of near-term clinical data in a capital efficient…View ↗
gavo-cel: our lead, first-in-class TRuC-T cell targeting mesothelin-expressing solid tumors (gavocabtagene autoleucel, formerly TC-210)View ↗
TC-510: our first enhanced TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptorView ↗
TC-520: our first TRuC-T cell targeting CD-70-expressing solid and liquid tumors which incorporates IL-15 pathway enhancements designed to…View ↗
Competes with Amgen, Bayer, Bristol-Myers Squibb, Eisai, F. Hoffmann-La Roche, Harpoon Therapeutics, Morphotek, Selecta Biosciences, Novimmune, Adaptimmune, Atara Biotherapeutics, CARISMA Therapeutics, Gracell Biotechnology, Kiromic Biopharma, Biotech, Takeda Pharmaceutical, and Tmunity Therapeutics
10-K for FY2022, filed Mar 23, 2023The overexpression of mesothelin by numerous solid tumors, combined with its low expression on mesothelial cells lining the pleura…View ↗
Loading...
